Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
radium-223 + radiotherapy
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Administration
- Intravenous, External Beam
01
Overview
radium-223 + radiotherapy is a combination therapeutic regimen being investigated for the treatment of bone-metastatic prostate cancer. Radium-223 dichloride is a targeted alpha-emitting radiopharmaceutical that acts as a calcium mimetic, selectively binding to areas of increased bone turnover (hydroxyapatite) within metastatic lesions. Once localized, it emits high-energy, short-range alpha particles that induce double-strand DNA breaks, leading to cell death while sparing surrounding bone marrow. This is combined with external beam radiotherapy, such as Stereotactic Body Radiotherapy (SBRT), to provide enhanced local control of specific metastatic sites. The University of Utah has conducted clinical trials (e.g., NCT03304483) evaluating this combination in hormone-naive men with oligometastatic disease, utilizing [18F]fluciclovine PET/CT as a companion imaging tool to assess treatment response in bone lesions.
- Brand names
- Xofigo
- Other names
- radium-223 dichloride + radiotherapyradium-223 + stereotactic body radiotherapyradium-223 + SBRTradium-223 + EBRT
02
Targets
DNA
Beyond the preview
Go deeper on radium-223 + radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on radium-223 + radiotherapy.